Verdant Scientific is developing a first-in-class, first-in-approach small molecule for the treatment of atopic dermatitis, more commonly known as eczema, which is poised to completely change the treatment of this chronic, inflammatory skin condition, which affects over 200 million people worldwide.
Verdant Scientific is an early stage biotech startup developing a first-in-class, first-in-approach small molecule (VDT-002) for the treatment of atopic dermatitis (AD), more commonly known as eczema. Eczema is a chronic inflammatory skin condition which significantly impacts the lives of more than 200M people worldwide. There is no cure for the condition, and current treatments seek to reduce the symptoms of the disease by modulating the body's immune response. Verdant's approach to treating AD is completely novel, and targets a primary driver of the signs and symptoms of the disease: the staphylococcus aureus bacteria which colonize AD patients' skin. It is widely known and has been extensively demonstrated in peer reviewed literature that s. aureus produces toxins that directly destroy the skin barrier and also induce pruritus, or itching. Our elegant mechanism of action does not kill the bacteria, but rather stops them from causing harm. This fact opens the door for VDT-002 being used not only in an acute flare setting, but in perpetuity in a prophylactic manner. Through continuous prophylactic use it is possible that VDT-002 can prevent the signs and symptoms of the disease - in other words, it may represent a "cure" for many patients suffering from the condition, and become a significant blockbuster drug in process.
Verdant Scientific was founded by Robert Rushenberg MBA, and Dr. Cassandra Quave PhD. Robert is a successful serial entrepreneur, inventor, published author, and former venture capitalist in the life sciences space, with a track record of successfully funded and exited companies. Dr. Quave is an Associate Professor of Dermatology and Human Health at Emory University, and was appointed an endowed professorship in 2023. Dr. Quave is also a Guggenheim Fellow, Fellow of the National Academy of Inventors, and a Fellow of the Explorers Club. Her research focuses on the documentation and biochemical analysis of plants used in the traditional medical treatment of infectious and inflammatory skin disease, and she has a substantial media profile, being featured on BBC, CNN, National Geographic, The New York Times, and many others. In addition to the experienced co-founders, Verant is working with numerous highly experienced CROs to advance their small molecules through FDA clearance.
Verdant Scientific is a stealth-mode startup. Please contact the company directly for additional information.
Verdant Scientific is a stealth-mode startup. Please contact the company directly for additional information.
Verdant Scientific is opening its Seed round of financing in February, with a target raise of $6.75M. Please contact the company directly for additional information regarding the raise.
Verdant Scientific is a stealth-mode startup. Please contact the company directly for additional information.
Verdant Scientific is a stealth-mode startup. Please contact the company directly for additional information.
